Clinical Characteristics and Prognosis of COVID-19 patients in Syria: A cross-sectional multicenter study.
COVID-19
Clinical characteristics
Prevalence
Prognosis
Syria
Journal
Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
05
04
2022
revised:
14
05
2022
accepted:
14
05
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
28
5
2022
Statut:
ppublish
Résumé
COVID-19 ignited a global pandemic that, in Syria, further strained a nation and its healthcare system already ravaged by years of war and sanctions. The first case in Syria was reported on March 22, 2020, and this is the first study that aimed to describe the clinical characteristics, comorbidities, and prognosis of COVID-19 patients in Syria. Demographic and clinical data for this cross-sectional prospective study were collected on COVID-19 patients with positive polymerase chain reaction tests who were admitted to Al Assad and Al Mouwasat university hospitals between April 1 and January 31 of 2021. This study included 701 patients. The majority were over age 60 (59%) and male (67.9%). The commonest symptoms were fever (86.6%) and shortness of breath (75.6%). The commonest comorbidities were hypertension (53.9%) and diabetes mellitus (41.5%). On multivariable analysis, risk factors found to be significantly associated with poor outcomes were advanced age (≥60 years); male gender; high respiratory rate (>35); respiratory failure (PaO₂/FiO₂ ratio<100); heart failure; chronic lung disease; elevated white blood cell counts, lactate dehydrogenase, c-reactive protein; prolonged international normalized ratio; and low lymphocyte counts. The clinical outcomes of our patients were as follows: 59.2% improved and were discharged from the hospital, 3.5% were discharged with persistent symptoms and 37.2% died. Several biomarkers can serve as early warning and prognostic indicators of severe illness and mortality from COVID-19 in the highest risk patients, especially males with multiple comorbidities over 60 years of age. In the context of a national healthcare system stretched thin by years of civil war and sanctions, and high COVID-19 mortality rates as a consequence, extra care should be taken to use the predictive power of these biomarkers to stratify high-risk patients in the earliest possible stages of the disease to minimize severe illness and reduce fatalities.
Sections du résumé
Background
UNASSIGNED
COVID-19 ignited a global pandemic that, in Syria, further strained a nation and its healthcare system already ravaged by years of war and sanctions. The first case in Syria was reported on March 22, 2020, and this is the first study that aimed to describe the clinical characteristics, comorbidities, and prognosis of COVID-19 patients in Syria.
Materials and methods
UNASSIGNED
Demographic and clinical data for this cross-sectional prospective study were collected on COVID-19 patients with positive polymerase chain reaction tests who were admitted to Al Assad and Al Mouwasat university hospitals between April 1 and January 31 of 2021.
Results
UNASSIGNED
This study included 701 patients. The majority were over age 60 (59%) and male (67.9%). The commonest symptoms were fever (86.6%) and shortness of breath (75.6%). The commonest comorbidities were hypertension (53.9%) and diabetes mellitus (41.5%). On multivariable analysis, risk factors found to be significantly associated with poor outcomes were advanced age (≥60 years); male gender; high respiratory rate (>35); respiratory failure (PaO₂/FiO₂ ratio<100); heart failure; chronic lung disease; elevated white blood cell counts, lactate dehydrogenase, c-reactive protein; prolonged international normalized ratio; and low lymphocyte counts. The clinical outcomes of our patients were as follows: 59.2% improved and were discharged from the hospital, 3.5% were discharged with persistent symptoms and 37.2% died.
Conclusion
UNASSIGNED
Several biomarkers can serve as early warning and prognostic indicators of severe illness and mortality from COVID-19 in the highest risk patients, especially males with multiple comorbidities over 60 years of age. In the context of a national healthcare system stretched thin by years of civil war and sanctions, and high COVID-19 mortality rates as a consequence, extra care should be taken to use the predictive power of these biomarkers to stratify high-risk patients in the earliest possible stages of the disease to minimize severe illness and reduce fatalities.
Identifiants
pubmed: 35620045
doi: 10.1016/j.amsu.2022.103816
pii: S2049-0801(22)00576-3
pmc: PMC9123823
doi:
Types de publication
Journal Article
Langues
eng
Pagination
103816Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
Gastroenterology. 2021 Jul;161(1):345-349
pubmed: 33811923
PLoS One. 2020 Dec 9;15(12):e0241956
pubmed: 33296367
Clin Infect Dis. 2020 Nov 19;71(16):2174-2179
pubmed: 32445579
Viruses. 2021 Mar 05;13(3):
pubmed: 33807920
Int J Surg. 2021 Dec;96:106165
pubmed: 34774726
Anesthesiology. 2020 Jun;132(6):1317-1332
pubmed: 32195705
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Virol J. 2021 Mar 17;18(1):58
pubmed: 33731169
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Aging (Albany NY). 2020 Jun 24;12(12):11245-11258
pubmed: 32633729
PLoS One. 2020 Jan 14;15(1):e0226997
pubmed: 31935226
Front Med (Lausanne). 2020 Jul 17;7:432
pubmed: 32766268
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Infect Dis Ther. 2021 Mar;10(1):421-438
pubmed: 33481202
Cell Metab. 2020 Jun 2;31(6):1068-1077.e3
pubmed: 32369736
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Int J Infect Dis. 2020 Jul;96:131-135
pubmed: 32376308
Medicine (Baltimore). 2016 Aug;95(32):e4495
pubmed: 27512866
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
J Thromb Thrombolysis. 2020 Nov;50(4):825-832
pubmed: 32761495
East Mediterr Health J. 2021 Jan 23;27(1):5-6
pubmed: 33538313
Aging (Albany NY). 2020 Apr 8;12(7):6049-6057
pubmed: 32267833
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
mBio. 2021 Feb 9;12(1):
pubmed: 33563817
Endocr Pract. 2021 Feb;27(2):95-100
pubmed: 33551315